SML3792

MRIA9 Trifluoroacetate

≥96% (HPLC)

• Sinónimos: 8-(((2r,5r)-5-Amino-1,3-dioxan-2-yl)methyl)-6-(2-chloro-4-(3-fluoropyridin-2-yl)phenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one trifluoroacetate, 8-[(trans -5-Amino-1,3-dioxan-2-yl)methyl]-6-[2-chloro-4-(3-fluoro-2-pyridinyl)phenyl]-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one trifluoroacetate
• Fórmula empírica (notación de Hill): C₂₄H₂₂ClFN₆O₃ · xC₂HF₃O₂
• Peso molecular: 496.92 (free base basis)
• UNSPSC Code: 12352200
• NACRES: NA.21
• MDL number: MFCD34474245
• Assay: ≥96% (HPLC)
• Form: powder
• Storage condition: desiccated

Propiedades

• Quality Segment: 100
• assay: ≥96% (HPLC)
• form: powder
• storage condition: desiccated
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: -10 to -25°C
• SMILES string: Fc1c(nccc1)c2cc(c(cc2)C3=Cc4c(nc(nc4)NC)N(C3=O)C[C@@H]5OC[C@H](CO5)N)Cl
• InChI key: QKNBRNSGPNCARD-SGNKCFNYSA-N

Descripción

Biochem/physiol Actions

ATP site-targeting, dual salt-inducible kinase (SIK1/2/3) & p21-activated kinase (PAK2/3) inhibitor with excellent selectivity over other kinases.

MRIA9 is an ATP site-targeting, dual salt-inducible kinase (SIK1/2/3 IC50 = 55/48/22 nM; SIK2/3 IC50 = 180/127 nM by cell-based NanoBRET) & p21-activated kinase (PAK2/3 IC50 = 41/140 nM; PAK1 IC50 = 580 nM) inhibitor with excellent selectivity over other kinases. MRIA9 sensitizes ovarian cancer cells to mitotic agent paclitaxel (Pac) treatment in SKOV3 cultures (1 nM Pac plus 0.5-5 µM MRIA9) and HeLa spheroids (2 nM Pac plus 5 µM MRIA9).

Disclaimer

Hygroscopic

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable